{
	"categories": {
		"data": [
			"18-Q1",
			"18-Q2",
			"18-Q3",
			"18-Q4",
			"19-Q1",
			"19-Q2",
			"19-Q3",
			"19-Q4"
		],
		"title": "Quarter"
	},
	"yaxis": "",
	"tickAmount":5,
	"mintick":0,
	"maxtick":50,
	"series": [
		{
			"name": "Drug A",
			"data": [
				25,
				25,
				24,
				14,
				13,
				13,
				12,
				12
			]
		},
		{
			"name": "Drug B",
			"data": [
				0,
				0,
				0,
				10,
				11,
				11,
				12,
				12
			]
		},
		{
			"name": "Drug C",
			"data": [
				25,
				26,
				26,
				27,
				27,
				28,
				28,
				29
			]
		},
		{
			"name": "Drug D",
			"data": [
				50,
				50,
				50,
				49,
				49,
				48,
				48,
				47
			]
		}
	],
	"keyinsights": [
		{
			"trend": "down",
			"text": "Market Share of Drug A has decreased by 13% from Q1-18 to Q4-19 due to an increase in Drug B’s market share which was launched on Q4’18"
		},
		{
			"trend": "down",
			"text": "Market Share of Drug A has decreased from 25%  in Q1-18 to 12% in Q4-19 due to a change in contract relative access from  P -> P to P->E"
		},
		{
			"trend": "up",
			"text": "For Drug A in Q4 2019, California state attributed to a growth of 15% in its Market compared to its market share in Q4 2018"
		},
		{
			"trend": "up",
			"text": "Market Share of Drug A from Provider1 has increased by 3% from Q1-19 to Q4-19 due to its inclusion under Payer1"
		}
	]
}